Clinical study of adefovir compared with entecavir in the treatment of chronic hepatitis B
10.13699/j.cnki.1001-6821.2015.04.005
- VernacularTitle:阿德福韦对比恩替卡韦治疗慢性乙型病毒性肝炎的临床研究
- Author:
Min SU
1
;
Zhen-Qiu SHANG
;
Ling-Feng LIANG
;
Xiao-Lin LAN
Author Information
1. 遂昌县人民医院 药剂科
- Keywords:
chronic hepatitis B;
adefovir;
entecavir;
clinical study
- From:
The Chinese Journal of Clinical Pharmacology
2015;(4):256-258
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of adefovir and entecavir in the treatment of chronic hepatitis B ( CHB ) . Methods Eighty -six patients with CHB were recruited from 2012 to 2013 in our hospital and randomly divided into adefovir group ( n=41 ) and entecavir group ( n=45 ) .Patients in the adefovir group and ente-cavir group were given adefovir 0.5 mg? d-1 , po and entecavir 10 mg? d-1 , po, respectively.The treatment lasted for 12 months.The he-patitis B virus( HBV) DNA, HBV negative rate and adverse drug reac-tions in two groups were compared before and after treatment.Results After 12 months treatment, the HBV DNA were significantly decreased in both groups [ ( 4.21 ±0.71 ) vs ( 4.01 ±0.68 ) log10 copies? mL-1 ] with statistical difference ( P <0.05 ) , but no statistical difference in HBV negative rate and ALT normal rate was found between the two groups ( P>0.05 ) .Conclusion Significant clinical efficacy of both adefovir and entecavir was found in the treatment of chronic hepatitis B, with less adverse drug reactions.
